tbuckley/cabot-search huggingface dataset:
Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation
Authors: Masanori Hasegawa, Raj Kumar Sinha, Manoj Kumar, Maroof Alam, Li Yin, Deepak Raina, Akriti Kharbanda, Govind Panchamoorthy, Dikshi Gupta, Harpal Singh, Surender Kharbanda, Donald Kufe
Journal: Clinical Cancer Research (2015)

Abstract Purpose: The MUC1-C oncoprotein is an intracellular target that is druggable with cell-penetrating peptide inhibitors. However, development of peptidyl drugs for treating cancer has been a challenge because of unfavorable pharmacokinetic parameters and limited cell-penetrating capabilities. Experimental Design: Encapsulation of the MUC1-C inhibitor GO-203 in novel polymeric nanoparticles was studied for effects on intracellular targeting of MUC1-C signaling and function. Results: Our results show that loading GO-203 into tetrablock polylactic acid (PLA)-polyethylene glycol (PEG)-polypropylene glycol (PPG)-PEG copolymers is achievable and, notably, is enhanced by increasing PEG chain length. In addition, we found that release of GO-203 from these nanoparticles is controllable over at least 7 days. GO-203/nanoparticle treatment of MUC1-C–positive breast and lung cancer cells in vitro was more active with less frequent dosing than that achieved with nonencapsulated GO-203. Moreover, treatment with GO-203/nanoparticles blocked MUC1-C homodimerization, consistent with on-target effects. GO-203/nanoparticle treatment was also effective in downregulating TIGAR, disrupting redox balance, and inhibiting the self-renewal capacity of cancer cells. Significantly, weekly administration of GO-203/nanoparticles to mice bearing syngeneic or xenograft tumors was associated with regressions that were comparable with those found when dosing on a daily basis with GO-203. Conclusions: These findings thus define an effective approach for (i) sustained administration of GO-203 in polymeric PLA-(PEG-PPG-PEG) nanoparticles to target MUC1-C in cancer cells and (ii) the potential delivery of other anticancer peptide drugs. Clin Cancer Res; 21(10); 2338–47. ©2015 AACR.
Intratumoral co-administration of interleukin-12 and angiostatin-like molecule by adenoviral mediated gene transfer in subcutaneously growing
Authors: Volker Schmitz, Lucia Tirado, Esther Raskopf, Jesus Prieto, Tilman Sauerbruch, Cheng Qian, Wolfgang Caselmann
Journal: Journal of Hepatology (2002)
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience
Authors: Anna Candoni, Erica Simeone, Mario Tiribelli, Michele Malagola, Domenico Russo, Renato Fanin
Journal: American Journal of Hematology (2009)
Abstract 3573: A small molecule PLK1 inhibitor, MLN0905, yields broad anti-tumor activity in human xenograft tumor models, and synergizes with taxane therapy
Authors: Kerri Lasky, Judy Shi, Vaishali Shinde, Bradley Stringer, Mark G. Qian, Debra Liao, Ray Liu, Matthew O. Duffey, Tricia J. Vos, Natalie D'Amore, Marc Hyer, Youlan Rao
Journal: Cancer Research (2011)

Abstract PLK1 is a serine/threonine mitotic kinase that plays a key role in mitotic cell cycle progression, and its over-expression has been linked to poor patient prognosis. We have discovered a potent and selective small molecule inhibitor of PLK1, MLN0905, which reduces cell viability and inhibits cell proliferation in a broad range of human tumor cells. We explored the pharmacokinetic, pharmacodynamic, and anti-tumor properties on MLN0905 in human xenograft models grown in rodents. MLN0905 rapidly and extensively distributed to xenograft tumor with a high tumor-to-plasma exposure ratio. In human xenograft tumor tissue, MLN0905 modulates the pharmacodynamic biomarker phospho-Histone H3 (in a dose dependent fashion), enabling us to track pathway modulation in vivo. MLN0905 demonstrated robust anti-tumor activity (partial and complete responses) in a variety of solid and hematological human xenograft models, including cancers derived from colon (HCT-116, HT29), NSCLC (Calu-6), Ovarian (SKOV3), and Lymphoma (OCI-LY19, OCI-LY10, and the primary lymphoma PHTX-22L). Significant anti-tumor activity was observed when dosing on either a continuous (daily) or intermittent schedule, underscoring the dosing flexibility with this compound. In the SKOV3 and Calu-6 xenograft models, MLN0905 yielded a synergistic anti-tumor response when combined with the standard of care therapy Taxane. This is the first report of a PLK1 inhibitor synergizing with taxane therapy in vivo. In summary, our findings indicate MLN0905 has good drug-like pharmacokinetic properties, modulates the biomarker phospho-Histone H3, and yields significant anti-tumor activity in multiple xenograft models. These preclinical data support further evaluating MLN0905 as a novel anti-cancer agent. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3573. doi:10.1158/1538-7445.AM2011-3573
Erythema and Conjunctivitis
Authors: Richard C. Rose
Journal: JAMA (1979)

During August to November 1977, fifty-eight episodes of erythema or conjunctivitis or both occurred among nursing-service employees at a large state hospital. Epidemiologic investigation implicated an ultraviolet-light— producing germicidal bulb in a nursing station's desk lamp as the causative agent. Removal of the lamp from the nursing station controlled the outbreak. Analysis of the spectral irradiance from the bulb suggested that the National Institute for Occupational Safety and Health exposure standards were exceeded in five to 20 minutes, depending on the individual's distance from the lamp. (<i>JAMA</i>242:1155-1156, 1979)
"TETANUS NEONATORUM."Read before the Section of Diseases of Children, at the Forty-second Annual Meeting of the American Medical Association, held at Washington, D. C., May, 1891.
Authors: B. A. WADDINGTON
Journal: JAMA (1891)

I have seen in a practice of over twenty-six years eight cases of "Trismus Neonatorum;" of these six have been fatal in their termination, two have recovered. I believe it to be of parasitic origin, the microorganism most likely a "coccus." I do not say that it never occurs in the lying-in room of the cleanly with proper aseptic surroundings, but know that in all the cases I have seen the environment has been one of filth and squalor. My experience shows that more cases occur among the negroes than among the whites. Of the eight cases seen seven were negro children and one white child. In the six fatal cases I resorted to the usual remedies: Calabar and chloral hydrate internally, chloroform by inhalation, ice to spine, Marion Sims' procedure of manipulation of occipital and parietal bones to relieve pressure upon medulla oblongata or cerebellum, but all of no
Clinical Trial Registries—Reply
Authors: Deborah A. Zarin, Nicholas C. Ide, Tony Tse, William R. Harlan, Donald A. B. Lindberg
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
INTERSTITIAL GINGIVITIS DUE TO AUTOINTOXICATIONAS INDICATED BY THE URINE AND BLOOD PRESSURE —DIAGNOSIS.
Authors: EUGENE S. TALBOT
Journal: JAMA (1906)

In a former paper, "Interstitial Gingivitis Due to Autointoxication," I discussed etiology; in my work on "Interstitial Gingivitis, or So-called Pyorrhea Alveolaris" I demonstrated the pathology; in this paper I propose to discuss the method of diagnosis in interstitial gingivitis. It has been demonstrated that this disease originates from autointoxication. It is justifiable, then, to state that interstitial gingivitis is dependent on the circulation and the vasomotor system. It is, then, a profitable subject for investigation. Before discussion of this phase of the subject, it is necessary to become familiar with the structures involved, which in themselves are unique. There are no other structures in the human body like them. I have gone into details many times in a description of these structures. I will now only discuss them in a general way. The alveolar process is a bony structure intended to hold the teeth in position; when the teeth
The Relationship of Cadmium in the Air to Cardiovascular Disease Death Rates
Authors: Robert E. Carroll
Journal: JAMA (1966)

The average concentration of cadmium in the air of the 28 cities for which data are available shows a marked correlation with death rates from hypertension and arteriosclerotic heart disease (coefficient of correlation [r] =0.76). This association cannot be explained by a tendency of large, industrialized cities to have both high heart disease rates and heavily polluted air, since there is no correlation with indexes of air pollution in general. Zinc, a closely related element, is the only other pollutant which correlates significantly (r=0.56). Previous studies have shown that patients with hypertension have increased cadmium levels in their renal tissue, and that small amounts can produce hypertensive disease in rats. It is difficult to explain all the current knowledge about cadmium, except by the hypothesis that it is a significant cause of hypertension and perhaps of a portion of the rest of the cardiovascular disease spectrum.
Opiates Transdeactivate Chemokine Receptors: δ and μ Opiate Receptor–mediated Heterologous Desensitization
Authors: M.C. Grimm, A. Ben-Baruch, D.D. Taub, O.M.Z. Howard, J.H. Resau, J.M. Wang, H. Ali, R. Richardson, R. Snyderman, J.J. Oppenheim
Journal: The Journal of Experimental Medicine (1998)

An intact chemotactic response is vital for leukocyte trafficking and host defense. Opiates are known to exert a number of immunomodulating effects in vitro and in vivo, and we sought to determine whether they were capable of inhibiting chemokine-induced directional migration of human leukocytes, and if so, to ascertain the mechanism involved. The endogenous opioid met-enkephalin induced monocyte chemotaxis in a pertussis toxin–sensitive manner. Met-enkephalin, as well as morphine, inhibited IL-8–induced chemotaxis of human neutrophils and macrophage inflammatory protein (MIP)-1α, regulated upon activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein 1, but not MIP-1β–induced chemotaxis of human monocytes. This inhibition of chemotaxis was mediated by δ and μ but not κ G protein–coupled opiate receptors. Calcium flux induced by chemokines was unaffected by met-enkephalin pretreatment. Unlike other opiate-induced changes in leukocyte function, the inhibition of chemotaxis was not mediated by nitric oxide. Opiates induced phosphorylation of the chemokine receptors CXCR1 and CXCR2, but neither induced internalization of chemokine receptors nor perturbed chemokine binding. Thus, inhibition of chemokine-induced chemotaxis by opiates is due to heterologous desensitization through phosphorylation of chemokine receptors. This may contribute to the defects in host defense seen with opiate abuse and has important implications for immunomodulation induced by several endogenous neuropeptides which act through G protein–coupled receptors.
Corrections to AASLD guidelines on chronic hepatitis B
Authors: Anna S. F. Lok, Brian J. McMahon
Journal: Hepatology (2007)

To the Editor: We would appreciate if corrections to Tables 2 and 10 in Lok and McMahon (HEPATOLOGY 2007;45:507–539) and a cautionary note on the use of entecavir in patients with hepatitis B virus (HBV)/human immunodeficiency virus (HIV) coinfection not simultaneously receiving highly active antiretroviral therapy (HAART) be brought to the attention of our readers. We deeply regret that Table 2 regarding who should be screened for HBV infection had an error: in the first bullet point, "South Asia" should be replaced with "Asia". Below is a corrected version of Table 2. Dose adjustments for telbivudine in patients with impaired renal function in Table 10 should also be revised to conform with the package insert as follows: We were also informed of a recent case report in which the selection of an HIV mutant containing the methionine-to-valine (M184V) substitution was found during entecavir treatment for chronic hepatitis B in an HBV/HIV coinfected patient who was not simultaneously receiving HAART.1 In light of this report, Bristol-Myers Squibb has advised caution regarding use of entecavir in this setting. Although the data is preliminary, we agree with the recommendations in the cautionary letter sent to all health care providers. Thus, until further data are available, we have revised recommendation #33 to read as: 33. Patients who are not on HAART and are not anticipated to require HAART in the near future should be treated with an antiviral therapy that does not target HIV, such as pegIFN-α, adefovir, or entecavir. Caution should be exercised if entecavir is used in this setting. Although telbivudine does not target HIV, it should not be used in this circumstance. (II-3)
Thanks, Adieu and Farewell
Authors: Inder M. Verma
Journal: Molecular Therapy (2004)

In 1999 did I assume The job of Editor-in-Chief of Molecular Therapy A journal new and just in bloom By the newly founded American Society of Gene Therapy. First, I asked many a friend and colleague To help and to serve on the Editorial Board Lucky I was to discover Fintan Steele As first Editor to get the show on the road. After hitches, glitches, and birthing pain Getting the publisher, printer, and schedule in line A few papers, reviews and confidence gained We published the first issue in January of 1999. Soon gene therapy suffered a grievous blow Jolted by the death of Jessie, the young boy Media, public and critiques all dimmed the glow Gene therapy, cried all, this event will destroy. Investigations, senate hearings, introspection of the field New rules, guidelines, new vectors, new ways emerged Papers, commentaries, new trials, left the copious yield Again optimism returned, gene therapy resurged Increased submissions, new interest, Molecular Therapy settled Fintan Steele unexpectedly chose to quit Editor's job The comfortable stance soon jarred and rattled Worried, hurried, with much help, soon we found Rob. Mid-2002 news traveled from France Cure of several children with SCID had no chance Gene therapy did work, for all to glance Left critics awed and us in a trance. Things sailed smoothly with the usual bumps New methods, new techniques did the field renew Every now and then came and were crossed humps Readership, impact factor, submissions all grew. Five years and fifty editorials gone by Many, many thanks for making Molecular Therapy number one It is now time to say good-bye So farewell all, my task is done!
Dual‐Imaging Enabled Cancer‐Targeting Nanoparticles
Authors: Aniket S. Wadajkar, Tejaswi Kadapure, Yi Zhang, Weina Cui, Kytai T. Nguyen, Jian Yang
Journal: Advanced Healthcare Materials (2012)

The development of dual-imaging enabled cancer-targeting nanoparticles (DICT-NPs) is reported based on newly developed biodegradable photoluminescent polymers and superparamagnetic iron oxide nanoparticles. DICT-NPs possess capabilities of dual-imaging (magnetic resonance imaging and optical imaging), magnetic targeting, and potentially selective targeting for cancer cells. The development of DICT-NPs addresses the concerns in dual-imaging nanoparticles where photobleaching organic dyes and cytotoxic quantum dots are usually adopted.
Care provision in England doesn't match regional variation in heart disease, study shows
Authors: Roger Dobson
Journal: BMJ (2007)

A new study that compared the prevalence of heart disease in different areas in England with the number of revascularisation procedures carried shows a mismatch between the two.

Some affluent areas with a low prevalence of disease had greater provision of procedures than more deprived areas with a high prevalence, says the study, published online in Health & Place (doi: 10.1016/j.healthplace.2007.04.003).

The study looked at data …
Secretory response of the human pancreas to continuous intravenous infusion of secretin.
Authors: J G Banwell, B E Northam, W T Cooke
Journal: Gut (1967)

EDITORIAL SYNOPSIS Measurement of the maximum secretory response of the pancreas is shown to be a valuable index of pancreatic function and the test is free from side effects.Secretin has been prepared in a pure form with an activity of 17,500 u./mg.by Jorpes and Mutt (1964), and using this preparation, Baron, Perrier, Janowitz, and Dreiling (1963) and Hansky, Tiscornia, Dreiling, and Janowitz (1964) demonstrated a maximum pancreatic response in dogs for both volume and bicarbonate with continuous intravenous secretin infusion in doses varying from 4 to 16 units per minute.The present study was undertaken to meas- ure the maximum secretory response of the human pancreas in normal subjects and in patients suspected of pancreatic disease and to compare these results with those of the standard secretin-pancreozymin tests described by Burton, Evans, Harper, Howat, Oleesky, Scott, and Varley (1960).MATERIAL NORMAL SUBJECTS Seven subjects, men and women aged 16 to 65 years of age, formed the control group.All had normal glucose tolerance tests, serum amylase levels, and faecal fat output, and were free of clinical and radiological evidence of pancreatic disease.
Economic models are not evolutionary models
Authors: Roger J. Sullivan, Henry F. Lyle, III
Journal: Behavioral and Brain Sciences (2005)

Henrich et al. reject the “selfishness axiom” within a narrowly-defined economic model, and are premature in claiming that they have demonstrated cross-cultural variability in “selfishness” as defined in broader evolutionary theory. We also question whether a key experimental condition, anonymity, can be maintained in the small, cohesive, social groupings employed in the study.
CHOREA IN THREE CHILDREN OCCUPYING SAME BEDROOM
Authors: R. G. Waller
Journal: BMJ (1932)

CLINICAL CASES Case 1.-A patient with erysipelas of the thigh and buttock was injected intradermally and subcutaneously with milk on April 25th, 1931, -Lt inches below the lower margin.On the following morning there was no spread downwards near the site of the injection, but the upper margin infection was spreading equally all round ; at 10 p.m. it was still spreading upwards; on the morning of April 27th there was intradermal injection along the centre of the upper margin.Next day there was no spread along the line at which the injection was made, but the infection had extended in the form of a horn on either side.The temperature returned to normal on the same day.Case 2.-A patient with erysipelas of the riglht arm had received omnadine and anti-streptococcal serum for three days without benefit.On the fourth day an injection (intradermal and subcutaneous) of milk was made at the distal margin.Next day the temperature was normal, and the infection had subsided.Case 3.-A patient with erysipelas on the inner side of the left elbow (temperature 103.70 F.) wNas cured in one day by a milk injection at the proximal margin.Case 4.-To a patient with erysipelas of the left leg was given one injection (intradermal) of 8 c.cm. of milk.No spread at the site of injection ensued, but there was some spread on the mesial aspect.The next day the patient was cured.
331 C-FOS ACCELERATES HEPATOCYTE SPREADING AND MOTILITY TRIGGERED BY EGF AND TGF-BETA COSTIMULATION THROUGH ERK-MEDIATED UPREGULATION OF PAXILLIN-SERINE178 PHOSPHORYLATION
Authors: M.C. Guller, J. Andre, A. Mauviel, F. Verrecchia, D. Bernuau
Journal: Journal of Hepatology (2008)
Diagnostic Evaluation of Suspected Genitourinary Tract Injury
Authors: Charles Rieser
Journal: JAMA (1967)

In suspected injuries of the urinary tract, complete assessment of the site and degree of injury should be promptly undertaken. Appropriate methods of diagnosis by x-ray examination and instrumentation are presently available permitting an orderly sequence of diagnostic steps, affording a high degree of accurate estimation of the extent of damage. Injuries of the kidney and ureter should be studied by means of excretory urography, either the conventional or infusion technique, as preliminary steps. In the event precise diagnosis has not been made, cystoscopy and retrograde pyelography should unhesitatingly be performed. Renal angiography offers clear x-ray visualization of both the vasculature and parenchyma of the injured kidney and, where facilities are available, should be employed. Retrograde cystography and urethrocystography are presently the most acceptable methods of appraisal of the disruption of the urinary bladder and urethra.
Single-lung transplantation for pulmonary hypertension. Three-month hemodynamic follow-up.
Authors: M K Pasque, E P Trulock, L R Kaiser, J D Cooper
Journal: Circulation (1991)

Shorter waiting times, relative technical simplicity, and satisfactory application to a broad spectrum of patients has made single-lung transplantation an attractive option in the treatment of patients with end-stage pulmonary hypertension.Seven patients with pulmonary hypertension underwent single-lung transplantation. Simultaneous closure of associated atrial septal defects was accomplished in two patients. Despite severely compromised pretransplant right ventricular function in all patients, there was no early or late mortality. Right ventricular functional recovery as characterized by hemodynamic assessment before and at a mean of 13 weeks posttransplant was nearly uniform and characterized by a drop in 1) pulmonary arterial systolic pressure from 92 +/- 7 mm Hg to 29 +/- 6 mm Hg (p = 0.001), 2) central venous pressure from 10 +/- 6 mm Hg to 1 +/- 2 mm Hg (p = 0.02), and 3) pulmonary vascular resistance index from 1,924 +/- 663 to 232 +/- 73 dyne.sec.cm-9 (p = 0.001). Radionuclide ventriculography before and at a mean of 17 weeks posttransplant documented a significant (p = 0.006) increase in right ventricular ejection fraction from 22 +/- 15% to 51 +/- 11%. Quantitative pulmonary perfusion scintigraphy at a mean of 17 weeks posttransplant demonstrated a significant (p = 0.001) increase in perfusion to the transplanted lung from 56 +/- 6% to 89 +/- 7%. There was a concomitant, slight but significant (p = 0.004) decrease in ventilation to the transplanted side from 56 +/- 6% to 49 +/- 8%. After transplantation, all patients returned to New York Heart Association functional class I or II from their preoperative levels of class III or IV.These early follow-up data cautiously support the option of single-lung transplantation in patients with pulmonary hypertension, although long-term durability of these hemodynamic changes deserves documentation before widespread application.